Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Clinical trial NCT07115485 · RECRUITING
Trial details
- NCT number
- NCT07115485
- Sponsor
- Shanghai Henlius Biotech
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-15
- Primary completion
- 2027-08-30
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.